Overview of Investigation into PetMed Express, Inc.
PetMed Express, Inc. (NASDAQ: PETS), a well-known company within the pet medication field, is under scrutiny for its recent disclosures relating to the potentially delayed release of its financial results. This has prompted an increasing concern among investors regarding the possible violations of federal securities laws.
Recent Developments
On June 10, a considerable shockwave traversed through the market as PetMed announced it would delay the release of its financial results for the fourth quarter and fiscal year. The company stated that this postponement was due to the requirement for additional time to complete the year-end audit process. Such announcements can typically lead to investor unease, and this instance was no different.
Impact on Shareholders
The immediate aftermath of the announcement saw PetMed's stock price take a hit, dropping $0.47 or 11.2% to a closing price of $3.72 per share. This decline signifies a significant loss for shareholders who had invested in the company based on anticipated performance outcomes reflected in financial reports.
What Should Investors Do?
For investors feeling the sting of this financial setback, it is vital to explore their available options. Engaging legal counsel can shed light on potential courses of action to recover losses stemming from these events. Investors are encouraged to gather documentation and hold discussions about the implications of these announcements.
Contact Information
To dive deeper into these events or to unfold any queries regarding this investigation and individual rights, investors should reach out directly to:
Charles Linehan, Esq.
Glancy Prongay & Murray LLP
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Email: shareholders@glancylaw.com
Visit our website: www.glancylaw.com.
Legal Guidance for Whistleblowers
If there are individuals who possess non-public information regarding PetMed, this could serve an integral role in the investigation. The SEC Whistleblower Program invites those with original insights into potential misconduct to come forward. Participants could be eligible for compensation of up to 30 percent of any recovery achieved by the SEC.
About Glancy Prongay & Murray LLP
Glancy Prongay & Murray LLP is respected nationally for advocating on behalf of investors and consumers. The firm specializes in securities and complex class action litigation, achieving notable settlements in securities class actions. With a team of nearly 40 attorneys across multiple locations, they have successfully led initiatives that have recovered billions for investors.
Frequently Asked Questions
What triggered the investigation into PetMed Express, Inc.?
The investigation was sparked by PetMed's announcement concerning a delay in releasing financial results, raising concerns among investors about the company's compliance with securities laws.
How much did PetMed's stock drop following the announcement?
PetMed's stock price decreased by $0.47, a drop of 11.2%, closing at $3.72 per share after the announcement.
What options do investors have to address their losses?
Investors are encouraged to seek legal advice to explore the potential for recovering losses stemming from PetMed's recent disclosures and any misconduct.
How can individuals help with the SEC investigation?
Individuals with non-public information may contact the firm involved to discuss how their insights could aid the investigation, potentially qualifying for rewards through the SEC Whistleblower Program.
What services does Glancy Prongay & Murray LLP offer?
They provide legal representation in securities litigation and protect the rights of investors and consumers affected by corporate misconduct and class actions.
